Mode
Text Size
Log in / Sign up

Nomogram model using NLR, age, and ultrasound features discriminates papillary thyroid carcinoma from benign nodules.

Nomogram model using NLR, age, and ultrasound features discriminates papillary thyroid carcinoma fro…
Photo by Nathan Rimoux / Unsplash
Key Takeaway
Consider a nomogram model using NLR, age, and ultrasound features to aid PTC diagnosis in thyroid nodules.

This multicenter cohort study included 1040 patients with thyroid nodules from Institutions A, B, C, and D. The population comprised patients with either papillary thyroid carcinoma or benign thyroid nodules. The study evaluated a nomogram model based on inflammatory biomarker NLR, patient age, and Ultrasound features to discriminate PTC from BTN. Safety and tolerability were not reported, and adverse events were not assessed.

The primary outcome was discrimination of PTC from BTN. In the training cohort (n=513), the AUC was 0.841 (95%CI: 0.807-0.872). In the internal validation cohort (n=220), the AUC was 0.828 (95%CI: 0.772-0.876). External validation in cohort 1 (n=164) yielded an AUC of 0.756 (95%CI: 0.683-0.820), while cohort 2 (n=143) showed an AUC of 0.833 (95%CI: 0.762-0.890). Bootstrap resamplings (n=1000) resulted in an AUC of 0.826 (95%CI: 0.798-0.852). Calibration, clinical applicability, and net clinical benefit were secondary outcomes.

The study design was a cohort study, not an RCT. Follow-up duration was not reported. Funding or conflicts were not reported. The study provides added value for the individualized diagnosis and treatment of PTC. Because the evidence is observational, causal language is avoided. The results indicate the model's performance but do not establish efficacy in changing clinical outcomes.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectivesThe predictive significance of lymphocyte-related inflammatory biomarkers for papillary thyroid carcinoma (PTC) remains unclear. This study aims to provide a new tool for differentiating PTC from benign thyroid nodule (BTN) by constructing a nomogram model.MethodsInstitution A (n=733) was randomly divided into a training cohort (n=513) and an internal validation cohort (n=220) at a 7:3 ratio. Institution B (n=164) served as external validation cohort 1, while Institutions C and D (n=143) were combined as external validation cohort 2. In the training cohort, a nomogram model was constructed by stepwise selection of features through univariate and multivariate logistic regression. The model’s discrimination, calibration, and clinical applicability were assessed using the area under the receiver operating characteristic curve (AUC), decision curve analysis (DCA), and clinical impact curve (CIC).ResultsThe final nomogram integrated the inflammatory biomarker NLR with patient age and Ultrasound(US) features. This model demonstrated excellent predictive performance across the training cohort (AUC 0.841, 95%CI: 0.807-0.872), internal validation cohort (AUC 0.828, 95%CI: 0.772-0.876), external validation cohort 1 (AUC 0.756, 95%CI: 0.683-0.820), and external validation cohort 2 (AUC 0.833, 95%CI: 0.762-0.890). DCA and CIC evaluations further confirmed the model’s good calibration and significant net clinical benefit.Additionally,1000 bootstrap resamplings in the entire dataset demonstrated robust diagnostic performance(AUC 0.826, 95%CI: 0.798-0.852).The nomogram maintained robust generalizability and clinical practical value across different centers, populations, and examination equipment.ConclusionThe nomogram model we developed has good diagnostic performance and provides added value for the individualized diagnosis and treatment of PTC.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.